Study identifier:D8220R00045
ClinicalTrials.gov identifier:NCT05437250
EudraCT identifier:N/A
CTIS identifier:N/A
A French multicentric observational study of acalabrutinib in the treatment of Chronic Lymphocytic Leukemia patients
Chronic Lymphocytic Leukemia
N/A
No
Non interventional study
All
350
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
CLL patients treated with acalabrutinib at their physician's discretion In each center, all patients meeting the inclusion criteria and no exclusion criteria will be offered to participate in this study. | - |